{"title":"TNF-α抑制剂对四氯化碳所致肾毒性的影响。","authors":"Ali Ozdemir, Levent Tumkaya, Suleyman Kalcan, Mikail Uyan, Ahmet Karakaya, Gokhan Demiral, Tugba Celik Samanci, Tolga Mercantepe, Medine Cumhur Cüre, Erkan Cüre","doi":"10.1080/10641963.2021.2018600","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Carbon tetrachloride (CCl<sub>4</sub>), employed in various industrial fields, can cause acute damage in renal tissues. This study investigated the therapeutic effect of the TNF-alpha inhibitor Infliximab on TGF-ß and apoptosis caused by acute kidney image induced by CCl<sub>4</sub>.</p><p><strong>Methods: </strong>Twenty-four male Sprague-Dawley rats were assigned into control, CCl<sub>4</sub>, and CCl<sub>4</sub>+ Infliximab groups. The control group received an isotonic saline solution, and the CCl<sub>4</sub> group 2 mL/kg CCl<sub>4</sub> intraperitoneally (i.p). The CCl<sub>4</sub>+ Infliximab group was given 7 mg/kg Infliximab 24 hours after administration of 2 mL/kg CCl<sub>4</sub>. Kidney tissues were removed at the end of the experiment and subjected to histopathological and biochemical analysis.</p><p><strong>Results: </strong>The application of CCl<sub>4</sub> led to tubular necrosis, inflammation, vascular congestion, and increased Serum BUN and creatinine values. An increase in caspase-3 activity also occurred in the CCl<sub>4</sub> group. However, Infliximab exhibited an ameliorating effect on kidney injury by causing a decrease in the number of apoptotic cells. Tissue ADA and TGF-ß values of the CCL4 group were significantly higher than the values of the control group (<i>p</i> = .001, <i>p</i> < .001 respectively) and CCL<sub>4</sub>+ Inf group (<i>p</i> = .004, <i>p</i> = .015, respectively).</p><p><strong>Conclusions: </strong>This study shows that Infliximab ameliorates nephrotoxicity by reducing lipid peroxidation, oxidative stress, and apoptosis in acute kidney damage developing in association with CCl<sub>4</sub> administration. These findings are promising in terms of the ameliorating role of TNF-alpha inhibitors in acute kidney injury.</p>","PeriodicalId":10333,"journal":{"name":"Clinical and Experimental Hypertension","volume":"44 3","pages":"291-296"},"PeriodicalIF":1.5000,"publicationDate":"2022-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"The effects of TNF-α inhibitors on carbon tetrachloride-induced nephrotoxicity.\",\"authors\":\"Ali Ozdemir, Levent Tumkaya, Suleyman Kalcan, Mikail Uyan, Ahmet Karakaya, Gokhan Demiral, Tugba Celik Samanci, Tolga Mercantepe, Medine Cumhur Cüre, Erkan Cüre\",\"doi\":\"10.1080/10641963.2021.2018600\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>Carbon tetrachloride (CCl<sub>4</sub>), employed in various industrial fields, can cause acute damage in renal tissues. This study investigated the therapeutic effect of the TNF-alpha inhibitor Infliximab on TGF-ß and apoptosis caused by acute kidney image induced by CCl<sub>4</sub>.</p><p><strong>Methods: </strong>Twenty-four male Sprague-Dawley rats were assigned into control, CCl<sub>4</sub>, and CCl<sub>4</sub>+ Infliximab groups. The control group received an isotonic saline solution, and the CCl<sub>4</sub> group 2 mL/kg CCl<sub>4</sub> intraperitoneally (i.p). The CCl<sub>4</sub>+ Infliximab group was given 7 mg/kg Infliximab 24 hours after administration of 2 mL/kg CCl<sub>4</sub>. Kidney tissues were removed at the end of the experiment and subjected to histopathological and biochemical analysis.</p><p><strong>Results: </strong>The application of CCl<sub>4</sub> led to tubular necrosis, inflammation, vascular congestion, and increased Serum BUN and creatinine values. An increase in caspase-3 activity also occurred in the CCl<sub>4</sub> group. However, Infliximab exhibited an ameliorating effect on kidney injury by causing a decrease in the number of apoptotic cells. Tissue ADA and TGF-ß values of the CCL4 group were significantly higher than the values of the control group (<i>p</i> = .001, <i>p</i> < .001 respectively) and CCL<sub>4</sub>+ Inf group (<i>p</i> = .004, <i>p</i> = .015, respectively).</p><p><strong>Conclusions: </strong>This study shows that Infliximab ameliorates nephrotoxicity by reducing lipid peroxidation, oxidative stress, and apoptosis in acute kidney damage developing in association with CCl<sub>4</sub> administration. These findings are promising in terms of the ameliorating role of TNF-alpha inhibitors in acute kidney injury.</p>\",\"PeriodicalId\":10333,\"journal\":{\"name\":\"Clinical and Experimental Hypertension\",\"volume\":\"44 3\",\"pages\":\"291-296\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2022-04-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Hypertension\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10641963.2021.2018600\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/12/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10641963.2021.2018600","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/12/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
The effects of TNF-α inhibitors on carbon tetrachloride-induced nephrotoxicity.
Objectives: Carbon tetrachloride (CCl4), employed in various industrial fields, can cause acute damage in renal tissues. This study investigated the therapeutic effect of the TNF-alpha inhibitor Infliximab on TGF-ß and apoptosis caused by acute kidney image induced by CCl4.
Methods: Twenty-four male Sprague-Dawley rats were assigned into control, CCl4, and CCl4+ Infliximab groups. The control group received an isotonic saline solution, and the CCl4 group 2 mL/kg CCl4 intraperitoneally (i.p). The CCl4+ Infliximab group was given 7 mg/kg Infliximab 24 hours after administration of 2 mL/kg CCl4. Kidney tissues were removed at the end of the experiment and subjected to histopathological and biochemical analysis.
Results: The application of CCl4 led to tubular necrosis, inflammation, vascular congestion, and increased Serum BUN and creatinine values. An increase in caspase-3 activity also occurred in the CCl4 group. However, Infliximab exhibited an ameliorating effect on kidney injury by causing a decrease in the number of apoptotic cells. Tissue ADA and TGF-ß values of the CCL4 group were significantly higher than the values of the control group (p = .001, p < .001 respectively) and CCL4+ Inf group (p = .004, p = .015, respectively).
Conclusions: This study shows that Infliximab ameliorates nephrotoxicity by reducing lipid peroxidation, oxidative stress, and apoptosis in acute kidney damage developing in association with CCl4 administration. These findings are promising in terms of the ameliorating role of TNF-alpha inhibitors in acute kidney injury.
期刊介绍：
Clinical and Experimental Hypertension is a reputable journal that has converted to a full Open Access format starting from Volume 45 in 2023. While previous volumes are still accessible through a Pay to Read model, the journal now provides free and open access to its content. It serves as an international platform for the exchange of up-to-date scientific and clinical information concerning both human and animal hypertension. The journal publishes a wide range of articles, including full research papers, solicited and unsolicited reviews, and commentaries. Through these publications, the journal aims to enhance current understanding and support the timely detection, management, control, and prevention of hypertension-related conditions.
One notable aspect of Clinical and Experimental Hypertension is its coverage of special issues that focus on the proceedings of symposia dedicated to hypertension research. This feature allows researchers and clinicians to delve deeper into the latest advancements in this field.
The journal is abstracted and indexed in several renowned databases, including Pharmacoeconomics and Outcomes News (Online), Reactions Weekly (Online), CABI, EBSCOhost, Elsevier BV, International Atomic Energy Agency, and the National Library of Medicine, among others. These affiliations ensure that the journal's content receives broad visibility and facilitates its discoverability by professionals and researchers in related disciplines.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
